ESSA Pharma Files Proxy Statement

TL;DR

ESSA Pharma filed its proxy statement, get ready to vote.

AI Summary

ESSA Pharma Inc. filed a Definitive Proxy Statement (DEFA14A) on September 30, 2025. This filing is related to the company's proxy materials, which are used to solicit votes from shareholders for upcoming meetings. The filing does not appear to contain specific financial transactions or major corporate events beyond the standard proxy statement requirements.

Why It Matters

Proxy statements are crucial for shareholder engagement, outlining proposals and information needed for voting on corporate matters.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not indicate any unusual financial activity or significant corporate changes.

Key Players & Entities

• ESSA Pharma Inc. (company) — Registrant
• 0001104659-25-095060 (filing_id) — Accession Number
• 20250930 (date) — Filing Date

FAQ

Filing Documents

• tm2527481d2_defa14a.htm (DEFA14A) — 56KB
• 0001104659-25-095060.txt ( ) — 57KB

01 Other Events

Item 8.01 Other Events. On September 30, 2025, ESSA Pharma Inc. (the " Company ") issued a press release announcing that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. (" Xeno "), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding common shares of the Company (the " Transaction "), the Company received an amended Interim Order from the Supreme Court of British Columbia (the " Court ") on September 25, 2025. The amended Interim Order approves the previously announced date for the Company's special meeting of the holders of common shares of the Company, optionholders and warrantholders (the " Special Meeting ") of October 3, 2025, the deadline to deliver notices of dissent of October 1, 2025, the Court hearing date for approval of the Arrangement of October 7, 2025 and the deadline of October 3, 2025 for responses for persons intending to attend the October 7 th hearing. ESSA's Special Meeting will reconvene at 2:00 p.m. (Pacific Time) on October 3, 2025. The Special Meeting will still be held online via a live interactive webcast on the internet at https://meetnow.global/MHPMJ4R. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward Looking Statements

Forward Looking Statements This communication, and any related oral statements, contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, " forward-looking statements "). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate," "believe," "plan," "estimate," "expect," and "intend," statements that an action or event "may," "might," "could," "should," or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction, and other statements that are not statements of historical facts. In this communication, these forward-looking statements are based on the Company's current expectations, estimates and projections regarding, among other things, the Special Meeting, the expected date of closing of the Transaction and the potential benefits thereof, the Company's business and industry, management's beliefs and certain assumptions made by the Company, all of which are subject to change. Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, and which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. Such statements reflect the Company's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Comp

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESSA PHARMA INC. (Registrant) Date: September 30, 2025 By: /s/ David Wood Name: David Wood Title: Chief Financial Officer Exhibit 99.1 ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, Sept. 30, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. (“Xeno”), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding common shares of ESSA (the “Transaction”), ESSA received an amended Interim Order from the Supreme Court of British Columbia (the “Court”) on September 25, 2025. The amended Interim Order approves the previously announced date for ESSA’s special meeting of the holders of common shares of the Company, optionholders and warrantholders (the “Special Meeting”) of October 3, 2025, the deadline to deliver notices of dissent of October 1, 2025, the Court hearing date for approval of the Arrangement of October 7, 2025 and the deadline of October 3, 2025 for responses for persons intending to attend the October 7 th hearing. ESSA’s Special Meeting will reconvene at 2:00 p.m. (Pacific Time) on October 3, 2025. The Special Meeting will still be held online via a live interactive webcast on the internet at https://meetnow.global/MHPMJ4R. ESSA filed supplemental proxy materials reflecting the previously announced revised terms of the Transaction on September 24, 2025 on the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca. About ESSA Pharma Inc.

Forward Looking Statements

Forward Looking Statements This communication, and any related oral statements, contains certain information which, as presented, constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” and “intend,” statements that an action or event “may,” “might,” “could,” “should,” or “will” be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction, and other statements that are not statements of historical facts. Page 1 of 3 In this communication, these forward-looking statements are based on the Company’s current expectations, estimates and projections regarding, among other things, the Special Meeting, the expected date of closing of the Transaction and the potential benefits thereof, the Company’s business and industry, management’s beliefs and certain assumptions made by the Company, all of which are subject to change. Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, and which may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. Such statements reflect the Comp

View Full Filing

View this DEFA14A filing on SEC EDGAR